{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-027969","form_type":"8-K","ticker":null,"cik":"0001733413","company_name":"TFF Pharmaceuticals, Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.288584+00:00","generated_at":"2026-06-17T05:15:07.287375+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"TFF Pharmaceuticals amends bylaws to adopt universal proxy rules and other governance changes","bullets":["Board approved First Amended and Restated Bylaws on March 31, 2023, effective immediately.","Section 2.14 adopts universal proxy provisions under Rule 14a-19 of the Exchange Act.","Section 2.12 permits stockholder action by majority written consent unless prohibited by charter.","Section 3.9 allows removal of directors with or without cause by majority vote of shares.","Other revisions reflect recent changes in Delaware General Corporation Law; no material impact on prior disclosures."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-027969","json":"https://secwatch.observer/filing/0001213900-23-027969.json","markdown":"https://secwatch.observer/filing/0001213900-23-027969.md","text":"https://secwatch.observer/filing/0001213900-23-027969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733413/000121390023027969/0001213900-23-027969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733413/000121390023027969/ea176605-8k_tffpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:15:07.287375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"903f2ef5f6d05100e5b5c37d6b7a7be0e036e3cd","claim":"TFF Pharmaceuticals, Inc.: Adopted First Amended and Restated Bylaws with universal proxy provisions, majority written consent for stockholder action, and director removal provisions (effective 2023-03-31).","evidence_excerpt":"On March 31, 2023, our Board of Directors approved and adopted our First Amended and Restated Bylaws (“Amended Bylaws”) of the Corporation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390023027969/0001213900-23-027969-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-31"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}